MARKET

INO

INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.52
+0.55
+4.59%
After Hours: 13.80 +1.28 +10.22% 17:15 12/03 EST
OPEN
12.24
PREV CLOSE
11.97
HIGH
13.38
LOW
12.22
VOLUME
16.50M
TURNOVER
--
52 WEEK HIGH
33.79
52 WEEK LOW
2.280
MARKET CAP
2.12B
P/E (TTM)
-9.2542
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Inovio Strikes Coronavirus Vaccine Manufacturing Deal With Kaneka Unit
Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against SARS-CoV-2, issued an update on its vaccine program Thursday, sending the stock high
Benzinga · 1h ago
Inovio signs COVID-19 vaccine manufacturing deal with Japan's Kaneka
Japan's Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals Inc's COVID-19 vaccine candidate, the U.S.-based vaccine maker said on Thursday. It did not disclose the terms of the agreement with Kaneka Eurogentec, a unit of the Japanese chemical company. Inovio has also signed manufacturing deals with medical device maker Thermo Fisher Scientific among others, to increase supply of the vaccine, which entered a mid-stage study last month.
Reuters · 8h ago
Inovio adds new member to manufacturing group for COVID-19 vaccine
Inovio Pharmaceuticals (INO) has added Kaneka Eurogentec S.A. to the consortium of companies that will manufacture COVID-19 vaccine candidate INO-4800.Kaneka joins Thermo Fisher Scientific, Richter-Helm BioLogics and Ology Biosciences.Financial terms
Seekingalpha · 8h ago
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition Of Kaneka Eurogentec S.A.
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A. PLYMOUTH MEETING, Pa., Dec. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
Benzinga · 9h ago
As Biotech Thrives On Vaccine Hopes, Traders Look Into The Sector's Diversity
If there is one prevailing trend that Wall Street is counting on during this period of great economic and social uncertainty, it’s the promise of biotech and pharmaceutical companies to seemingly save the world.
Benzinga · 1d ago
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis Report 2020: Regulatory Framework for COVID-19 Therapeutics and Vaccines Marketing Approvals
, /PRNewswire/ -- The report has been added to offering.  
PR Newswire - PRF · 3d ago
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
Zacks · 3d ago
Thinking about buying stock in AMC Entertainment, Inovio Pharmaceuticals, Sundial Growers, Nikola Corp, or Sorrento Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, INO, SNDL, NKLA, and SRNE.
PR Newswire - PRF · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INO stock price target is 13.71 with a high estimate of 25.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 334
Institutional Holdings: 62.40M
% Owned: 36.83%
Shares Outstanding: 169.41M
TypeInstitutionsShares
Increased
86
7.37M
New
95
-918.35K
Decreased
46
2.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.08%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Shea
Chief Operating Officer
Jacqueline Elizabeth Shea
Chief Scientific Officer
Laurent Humeau
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Jay Shepard
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.